by James Dye | Apr 17, 2024 | Press Releases
*Presentation to be held on Wednesday, April 24, from 2:00 – 2:15 p.m. SGT LEHI, Utah, April 17, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat... by James Dye | Mar 12, 2024 | Press Releases
Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET LEHI, Utah, March 12, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule... by James Dye | Feb 21, 2024 | Press Releases
LEHI, Utah, Feb. 21, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that David J. Bearss, Ph.D., President and CEO of... by James Dye | Feb 15, 2024 | Press Releases
The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15, 2024 /PRNewswire/... 
by Halia Therapeutics | Feb 6, 2024 | Press Releases
This technology will support the development of Halia’s new Alzheimer’s disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2) LEHI,... 
by Halia Therapeutics | Jan 31, 2024 | Press Releases
Series C Financing will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia’s first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic. LEHI, Utah, January 31,... by Halia Therapeutics | Jan 4, 2024 | Press Releases
LEHI, Utah, Jan. 4, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company, is pioneering a novel class of small molecule medications designed to combat inflammation. Today, the company announced that its leadership team will attend... by Halia Therapeutics | Dec 15, 2023 | Press Releases
LEHI, Utah, Dec. 15, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that the company will present at the 13th... 
by Halia Therapeutics | Dec 13, 2023 | Press Releases
LEHI, Utah, Dec. 13, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the dosing of the first patient in Phase 2a clinical... 
by Halia Therapeutics | Dec 8, 2023 | Press Releases, News & Media
The Phase II trial of HT-6184 will enroll around 50 patients with MDS who are or are on the borderline of being transfusion-dependent. Halia Therapeutics is looking to start a Phase II trial of its pipeline candidate HT-6184 in myelodysplastic syndrome (MDS) early... 
by Halia Therapeutics | Nov 29, 2023 | News & Media, Press Releases
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced positive results following the... by Halia Therapeutics | Nov 27, 2023 | Press Releases
Halia will present 3 posters with new positive data and a company showcase providing an overview of its clinical programs targeting the inflammasome LEHI, Utah, Nov. 27, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company... 
by Halia Therapeutics | Nov 20, 2023 | Press Releases
LEHI, Utah, Nov. 20, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced... 
by Halia Therapeutics | Nov 16, 2023 | Press Releases
SALT LAKE CITY, Nov. 16, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the... 
by Halia Therapeutics | Oct 31, 2023 | Press Releases
Company announces the appointment of Dr. David Bearss, CEO of Halia Therapeutics, as a member of the Board of Directors at BioUtah LEHI, Utah, Oct. 31, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative... by Halia Therapeutics | Oct 18, 2023 | Press Releases
LEHI, Utah, Oct. 18, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that Jared Bearss,... by Halia Therapeutics | Aug 31, 2023 | Press Releases
SALT LAKE CITY, Aug. 31, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced they... 
by Halia Therapeutics | Aug 22, 2023 | Press Releases
The company plans to start two Phase II trials later this year, with a further Phase I trial planned for early 2024. Halia Therapeutics is planning to start two Phase II trials evaluating its lead drug HT-6184 before the end of the year, said CEO David Bearss in an... by Halia Therapeutics | Aug 16, 2023 | Press Releases
SALT LAKE CITY, Aug. 16, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the opening of its... by Halia Therapeutics | Aug 7, 2023 | Press Releases
– Halia expects to release data from the Phase I trial in Q4 2023 SALT LAKE CITY, Aug. 7, 2023 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases that are driven... 